On Tuesday, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s shares declined -6.59% to $1.70.
AVEO Pharmaceuticals, Inc. (AVEO) declared the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and administration, and will serve on the executive leadership team which governs corporate strategy. He will report to Michael Bailey, AVEO’s president and chief executive officer.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
Coach Inc (NYSE:COH)’s shares dropped -6.33% to $39.65.
Coach Inc (COH) declared sales of $929 million for its third fiscal quarter ended March 28, 2015, contrast with $1.10 billion stated in the same period of the preceding year, a decrease of 15%. Stated sales would have been 3% higher not taking into account the impact of currency. Net income for the period totaled $100 million, with earnings per diluted share of $0.36, not taking into account transformation-related charges. Stated net income totaled $88 million, with earnings per diluted share of $0.32. This contrast to net income of $191 million and earnings per diluted share of $0.68 in the preceding year’s third quarter.
Coach, Inc. provides luxury accessories and lifestyle collections for women and men in the United States and internationally. It offers handbags, money pieces, wristlets, rings, charms, and cosmetic cases for women; and business cases, computer bags, messenger-style bags, totes, wallets, card cases, and belts, in addition to time administration and electronic accessories for men.
At the end of Tuesday’s trade, You On Demand Holdings, Inc. (NASDAQ:YOD)‘s shares dipped -5.24% to $2.17.
You On Demand Holdings, Inc. (YOD) declared a planned partnership with C Media, where YOD’s YOU Cinema service will become accessible to tens of millions of train passengers through C Media’s proprietary and recently launched railway Wi-Fi service platform.
In 2014, C Media secured the concession rights, via the appropriate regional railway administrations, to exclusively operate the Wi-Fi service on express and high-speed trains. To date, C Media has about 1,000 trains under its concession agreements and 140 trains already installed with C Rail Wi-Fi, making C Media the largest railway carriage Wi-Fi service provider in China, with immediate access to over 70 million captive consumers on board these 140 trains, annually. Once fully rolled out to all 1,000 trains, C Rail Wi-Fi will become a major gateway for YOU On Demand to access several hundred million travellers each year.
YOU On Demand Holdings, Inc., through its auxiliaries, provides integrated value-added service solutions for the delivery of video on demand and improved premium content for digital cable providers, Internet protocol television providers, over-the-top streaming providers, and mobile manufacturers and operators in the People’s Republic of China
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), ended its Tuesday’s trading session with -6.01% loss, and closed at $9.22.
ZIOPHARM Oncology Inc. (ZIOP) declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The study will be conducted at the Memorial Sloan Kettering Cancer Center in New York led by principal investigator Heather L. McArthur, M.D., M.P.H., Assistant Attending Physician, Breast Medicine Service, Memorial Sloan Kettering Cancer Center. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, an important protein for collapsing tumor stroma and stimulating an anti-cancer T cell immune response.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
